What is Autobio Diagnostics Co., Ltd.'s (603658.SS) StockRank?

MoatMap's StockRank for Autobio Diagnostics Co., Ltd. (603658.SS) is 94/100, with a Strong Buy signal. This is a composite score combining Quality (75), Value (62), and Momentum (50) factor ranks across MoatMap's 20,000+ stock universe.

Does Autobio Diagnostics Co., Ltd. have an economic moat?

Autobio Diagnostics Co., Ltd. (603658.SS) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Autobio Diagnostics Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Autobio Diagnostics Co., Ltd. (603658.SS) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Autobio Diagnostics Co., Ltd. in?

Autobio Diagnostics Co., Ltd. (603658.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603658.SS

STRONG BUYREMOVE

Autobio Diagnostics Co., Ltd. · Healthcare · China · $2.8B · Avg Vol: $13M/d

StockRank

P/E (TTM)

17.7x

ROE

11.5%

D/E

0.0x

Dividend %

4.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Autobio Diagnostics is a solid in-vitro diagnostics player with good quality metrics. However, it lacks alignment with our high-conviction themes, particularly the CDMO pricing power cycle, as it focuses on diagnostic kits rather than contract therapeutics manufacturing.

COMPANY DESCRIPTION

Autobio Diagnostics is a leading Chinese developer and manufacturer of in vitro diagnostic (IVD) instruments and reagents, with a primary focus on immunoassay, microbiology, and biochemistry. The company possesses a strong competitive moat driven by its advanced chemiluminescence immunoassay (CLIA) technology and a massive installed base in Chinese hospitals. It is a key driver of domestic import substitution in China's rapidly growing clinical diagnostics market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	656M	657M	661M	625M	-1.6%
EPS	0.30	0.31	0.31	0.28	-2.2%
Shares	586M	586M	581M	571M	-2.5%
Debt	20M	107M	81M	9M	-23.6%
Equity	1.2B	1.3B	1.3B	1.3B	4.7%
Op CF	230M	217M	194M	198M	-4.9%
Inv CF	-145M	-116M	-175M	-61M	—
Fin CF	-32M	-50M	-171M	-118M	—

PRICE (1M)-10.5%

SMA 50SMA 200

$4.51

RSI (14)

38.7

52W High

$6.07

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

12.8%80.5

ROE

11.5%75.5

GP/Assets

22.4%51.1

Op. Margin

25.0%88.3

FCF/Assets

12.4%91.0

Piotroski

—83.4

Int. Cover

50.0x91.5

D/E Ratio

0.01x90.6

Current Ratio

2.67x48.6

Value

P/E (TTM)

17.7x64.0

EV/EBITDA

11.5x37.9

P/FCF

85.7x77.2

P/B

2.0x55.1

P/S

4.3x44.5

Div Yield

4.2%86.4

Momentum

52W High %

74%63.6

RS 6M

-21%54.8

SMA 50/200

0.92x39.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+54%55.9

Q Growth

-12%30.7

FUNDAMENTALS

Market Cap

$2.8B

P/E (Forward)

11.6x

Gross Margin

64.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603658.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603658.SS	Autobio Diagnostics Co., Ltd.(you)	$2.8B	94	STRONG BUY
301087.SZ	Cofoe Medical Technology Co.,Ltd.	$1.6B	92	STRONG BUY
688016.SS	Shanghai MicroPort Endovascular MedTech Co., Ltd.	$1.9B	88	STRONG BUY
300206.SZ	Edan Instruments, Inc.	$1.2B	94	STRONG BUY
300529.SZ	Jafron Biomedical Co.,Ltd.	$2.1B	80	STRONG BUY
1789.HK	AK Medical Holdings Limited	$828M	95	STRONG BUY
002901.SZ	Double Medical Technology Inc.	$2.5B	70	BUY
600587.SS	Shinva Medical Instrument Co.,Ltd.	$1.2B	84	STRONG BUY
1302.HK	LifeTech Scientific Corporation	$932M	84	STRONG BUY
603387.SS	Getein Biotech, Inc	$668M	90	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Autobio Diagnostics Co., Ltd. (603658.SS) — Stock Score Summary

Autobio Diagnostics Co., Ltd. (603658.SS) has a MoatMap StockRank of 94/100 based on Quality (75/100), Value (62/100), and Momentum (50/100) factor scores. The current signal is STRONG BUY. Autobio Diagnostics is a solid in-vitro diagnostics player with good quality metrics. However, it lacks alignment with our high-conviction themes, particularly the CDMO pricing power cycle, as it focuses on diagnostic kits rather than contract therapeutics manufacturing.

Key Financial Metrics

Price	$4.51
Market Cap	$2.8B
P/E (TTM)	17.75
P/E (Forward)	11.55
Price/Book	2.00
Return on Equity	11.5%
Return on Invested Capital	12.8%
Debt/Equity	0.74
Gross Margin	64.8%
Operating Margin	25.0%
Revenue Growth	-0.4%
Dividend Yield	4.2%
Free Cash Flow	$33M

Autobio Diagnostics Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Autobio Diagnostics Co., Ltd.’s (603658.SS) StockRank?: MoatMap’s StockRank for Autobio Diagnostics Co., Ltd. (603658.SS) is 94/100, with a Strong Buy signal. It is a composite of Quality (75), Value (62), and Momentum (50) factor ranks across MoatMap’s 20,000+ stock universe.
Does Autobio Diagnostics Co., Ltd. have an economic moat?: Autobio Diagnostics Co., Ltd. (603658.SS) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Autobio Diagnostics Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Autobio Diagnostics Co., Ltd. (603658.SS) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Autobio Diagnostics Co., Ltd. in?: Autobio Diagnostics Co., Ltd. (603658.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).